Calendario›ONC›sonrotoclax
sonrotoclax
A Study of Sonrotoclax (BGB-11417) in Children With Relapsed or Refractory Acute Myeloid Leukemia and B-cell Acute Lymphoblastic Leukemia
Ensayo de BeOne Medicines Ltd. en Relapsed Acute Myeloid Leukemia · Refractory Acute Myeloid Leukemia · B-cell Acute Lymphoblastic Leukemia · Pediatric Cancer · Pediatric ALL, Relapsed · Pediatric ALL · Pediatric ALL, B Cell · Acute Myeloid Leukemia · Acute Lymphoblastic Leukemia · Pediatric AML · R/R AML · R/R B-cell ALL (del registro, en inglés).
Más ensayos de: Leucemia mieloide aguda · Leucemia linfoblástica aguda.
- Fase
- Fase 1/2
- Estado
- Aún sin reclutar
- Participantes
- 30
- Fin del objetivo primario
- abr 2030
Qué significa cada fase y cada estado.
Estudio de intervención, no aleatorizado, abierto. Comenzó en oct 2026.
Qué mide
Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) (From first dose of study drug to 30 days after last dose; up to approximately 12 months in cohort 1 and 4 months in cohort 2.) (del registro, en inglés)
Cómo lo describe el promotor
En el documentoEn inglés, del registroThe goal of this clinical trial is to learn if sonrotoclax (BGB-11417) is safe and may help treat children and adolescents with acute myeloid leukemia (AML) or acute lymphoblastic leukemia (ALL) that has come back after treatment or has not responded to treatment. The study will also learn how the body processes sonrotoclax when it is given with other medicines. The main questions it aims to answer are: * Is sonrotoclax safe and well tolerated when given with other anti-cancer medicines? * How does the body absorb, process, and remove sonrotoclax? * Does treatment with sonrotoclax, in combination with other medicines, help reduce or eliminate leukemia? Researchers will give sonrotoclax together with other anti-cancer medicines to participants with relapsed or refractory AML or ALL. Participants will: * Take sonrotoclax in combination with other anti-cancer medicines * Have regular clinic visits for physical exams, blood tests, heart monitoring, and other safety assessments. * Provide blood samples to measure how the body processes sonrotoclax. * Have tests to evaluate how their leukemia responds to treatment. * Continue treatment as long as it is helping and side effects remain manageable, according to the study plan.
Más ensayos de ONC
| Ensayo | Fase | Estado | Lectura de resultados |
|---|---|---|---|
| Sonrotoclax | Fase 1/2 | En marcha, sin reclutar | jul 2025 (real) |
| zanubrutinib · MANGROVE | Fase 3 | En marcha, sin reclutar | abr 2026 (real) |
| Sonrotoclax | Fase 2 | En marcha, sin reclutar | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Sonrotoclax Tablet for Oral… | Fase 1 | Reclutando pacientes | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| BGB-58067 | Fase 1 | Reclutando pacientes | sep 2026 (prevista, ya pasada: sin actualizar en el registro) |
| Sonrotoclax | Fase 1/2 | Reclutando pacientes | nov 2026 (prevista) |
Todos los de ONC, en su ficha.
Ficha completa en ClinicalTrials.gov (NCT07770698), actualizada en ago 2026.